


Triciribine phosphate

Chemical Properties

CAS No. :	61966-08-3
Formula:	C ₁₃ H ₁₇ N ₆ O ₇ P
Molecular Weight:	400.28
Storage:	Keep away from moisture Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Triciribine phosphate (VD 002) is a highly selective AKT inhibitor that induces cell cycle arrest and cysteinyl asparagin-dependent apoptosis, inhibits neovascularization, and can be used in the study of leukemia.
Targets(IC50)	Apoptosis,ATPase,Akt

Solubility Information

Solubility	DMSO: 8.06 mg/mL (20.14 mM),Sonication is recommended. H ₂ O: 5 mg/mL (12.49 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4983 mL	12.4913 mL	24.9825 mL
5 mM	0.4997 mL	2.4983 mL	4.9965 mL
10 mM	0.2498 mL	1.2491 mL	2.4983 mL
50 mM	0.050 mL	0.2498 mL	0.4997 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- E C Moore, Inhibition of two enzymes in de novo purine nucleotide synthesis by tricyridine phosphate (TCN-P). *Biochem Pharmacol.* 1989, 38, 22.
- Kim R, et al. Tricyridine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells. *Anticancer Res.* 2015 Sep;35(9):4599-604.
- Wu H, et al. Pharmacological inhibiting STAT5 for the treatment of FLT3-ITD-positive acute myeloid leukemia with tricyridine phosphate monohydrate. *MedComm (2020).* 2023 Jun 21;4(4):e294.
- Garrett CR, et al. Phase I pharmacokinetic and pharmacodynamic study of tricyridine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. *Invest New Drugs.* 2011 Dec;29(6):1381-9.
- Sampath D, et al. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor tricyridine phosphate monohydrate in patients with advanced hematologic malignancies. *Leuk Res.* 2013 Nov;37(11):1461-7.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481